Mengli Huang

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Venues

OncoTargets and therapy

Cancer management and research

Clinical cancer research : an official journal of the American Association for Cancer Research

3D Medicines Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

3D Medicines Inc. Mar 21 2016

China

Senior Medical Advisor :: The Medical Department

Publications

Weiming Fan, Chuan Wang, Xuefeng Zhong, Yating Zheng, Tingting Chen, Mengli Huang, Shuying Su
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib. OncoTargets and therapy 16 (2023)
Weiming Fan, Chuan Wang, Xuefeng Zhong, Yating Zheng, Tingting Chen, Mengli Huang, Shuying Su
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib. OncoTargets and therapy 16 (2023)
Zhisheng Liu, Junling Zhang, Yunjie Ge, Mengli Huang, Ye Wang
Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report. Cancer management and research 15 (2023)
Zhisheng Liu, Junling Zhang, Yunjie Ge, Mengli Huang, Ye Wang
Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report. Cancer management and research 15 (2023)
Xin Liu, Yuankai Shi, Huijie Wang, Xianghua Wu, Wangjun Yan, Yong Chen, Yu Xu, Chunmeng Wang, Weiqiang Yao, Jian Wang, Lin Yu, Jiashun Miao, Hao Chen, Jing Xia, Mengli Huang, Xiaowei Zhang, Zhiguo Luo
Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Gang Shen, Yinping Du, Jifang Shen, Junling Zhang, Xihua Xia, Mengli Huang, Wenxiang Shen
Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report. OncoTargets and therapy 14 (2021)
Zhiwei Xiao, Xuewu Huang, Biyuan Xie, Wenzhuan Xie, Mengli Huang, Li-Zhu Lin
Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement. OncoTargets and therapy 13 (2020)

Mengli Huang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mengli Huang